文献速递呼吸道感染

高剂量与低剂量地塞米松对住院中重度COVID-19肺炎患者临床恶化的影响:一项开放标签随机临床试验

Effect of high versus low dose of dexamethasone on clinical worsening in patients hospitalised with moderate or severe COVID-19 pneumonia: an open-label, randomised clinical trial.
PubMed 文献 · Eur Respir J · 2022-08-04

本研究为随机开放标签对照试验,纳入200例需氧疗的住院COVID-19肺炎患者,比较低剂量地塞米松(6 mg每日一次共10天)与高剂量方案(20 mg每日一次共5天,后10 mg每日一次共5天)。主要终点为随机化后11天内临床恶化,高剂量组发生率16.3%显著低于低剂量组31.4%(率比0.427,95%CI 0.216-0.842;P=0.014)。28天死亡率两组无显著差异(5.9% vs 6.1%,P=0.844),恢复时间及第5、11、14、28天七分类量表评分亦无显著差异。

要点

  • 高剂量地塞米松较地塞米松6 mg每日一次显著降低11天内临床恶化风险。
  • 高剂量与低剂量组28天死亡率无显著差异(5.9% vs 6.1%,P=0.844)。
  • 恢复时间及第5、11、14、28天临床状态量表评分两组无显著差异。

核心结论

  • 在需氧疗的住院COVID-19肺炎患者中,高剂量地塞米松较低剂量减少随机化后11天内的临床恶化。

研究设计与样本

  • 随机、开放标签、对照试验,纳入200例确诊COVID-19肺炎且需氧疗的住院患者。
  • 患者按1:1随机分配接受低剂量地塞米松(6 mg每日一次共10天)或高剂量地塞米松(20 mg每日一次共5天,后10 mg每日一次共5天)。
  • 主要终点为随机化后11天内临床恶化;次要终点包括28天死亡率、恢复时间及第5、11、14、28天七分类量表临床状态。

主要发现

  • 低剂量组102例中32例(31.4%)出现11天内临床恶化,高剂量组98例中16例(16.3%)出现(率比0.427,95%CI 0.216-0.842;P=0.014)。
  • 28天死亡率低剂量组为5.9%,高剂量组为6.1%(P=0.844)。
  • 恢复时间及第5、11、14、28天七分类量表评分两组无显著差异。

关键数值与推荐

  • 低剂量地塞米松方案:6 mg每日一次,共10天。
  • 高剂量地塞米松方案:20 mg每日一次共5天,随后10 mg每日一次共5天。
  • 主要终点率比0.427(95%CI 0.216-0.842;P=0.014),28天死亡率组间P=0.844。

临床怎么用

  • 对于需氧疗的住院中重度COVID-19肺炎患者,可考虑高剂量地塞米松以降低短期临床恶化风险。
  • 高剂量方案未显示28天死亡率获益,临床决策需结合患者个体情况权衡。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Low-dose dexamethasone demonstrated clinical improvement in patients with coronavirus disease 2019 (COVID-19) needing oxygen therapy; however, evidence on the efficacy of high-dose dexamethasone is limited. METHODS: We performed a randomised, open-label, controlled trial involving hospitalised patients with confirmed COVID-19 pneumonia needing oxygen therapy. Patients were randomly assigned in a 1:1 ratio to receive low-dose dexamethasone (6 mg once daily for 10 days) or high-dose dexamethasone (20 mg once daily for 5 days, followed by 10 mg once daily for an additional 5 days). The primary outcome was clinical worsening within 11 days since randomisation. Secondary outcomes included 28-day mortality, time to recovery and clinical status at day 5, 11, 14 and 28 on an ordinal scale ranging from 1 (discharged) to 7 (death). RESULTS: A total of 200 patients (mean±sd age 64±14 years; 62% male) were enrolled. 32 (31.4%) out of 102 patients enrolled in the low-dose group and 16 (16.3%) out of 98 in the high-dose group showed clinical worsening within 11 days since randomisation (rate ratio 0.427, 95% CI 0.216-0.842; p=0.014). The 28-day mortality was 5.9% in the low-dose group and 6.1% in the high-dose group (p=0.844). There was no significant difference in time to recovery, and in the seven-point ordinal scale at days 5, 11, 14 and 28. CONCLUSIONS: Among hospitalised COVID-19 patients needing oxygen therapy, high dose of dexamethasone reduced clinical worsening within 11 days after randomisation, compared with low dose.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Taboada M, Rodríguez N, Varela PM, et al. Effect of high versus low dose of dexamethasone on clinical worsening in patients hospitalised with moderate or severe COVID-19 pneumonia: an open-label, randomised clinical trial. Eur Respir J. 2022. PMID: 34916266. doi:10.1183/13993003.02518-2021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。